secwatch.observer — SEC 8-K summary
======================================

Issuer:     Genprex, Inc. (GNPX)
CIK:        0001595248
Form:       8-K
Filed at:   2025-10-28T23:59:59+00:00
Accession:  0001437749-25-031856
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Genprex reports positive preclinical data for Reqorsa in ALK+ NSCLC at AACR-NCI-EORTC
--------------------------------------------------------------------------------

- REQORSA overexpressed TUSC2 tumor suppressor gene in ALK-EML4+ NSCLC cell lines and patient derived organoids.
- Treatment induced apoptosis in ALK+ cells, including those resistant to alectinib; combination with alectinib further increased apoptosis.
- In mouse xenograft model, REQORSA + alectinib improved survival vs control, suggesting potential for future clinical trial.
- Data presented at 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1595248/000143774925031856/0001437749-25-031856-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1595248/000143774925031856/gnpx20251024c_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-031856

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer